These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38597374)

  • 1. Pharmacodynamic of Recombinant Human Interferon Alpha-2b Nasal Drops and Effective Prophylaxis Against SARS-COV-2 Infection.
    Nodarse-Cuni H; Bravo O; Cañete R; Vázquez-Blomquist D; Quintana D; Aguilera-Barreto A; Guillen-Nieto G; Arteaga A; Morales I
    J Interferon Cytokine Res; 2024 Jun; 44(6):271-280. PubMed ID: 38597374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Experience with Cuban Biotech's Nasalferon to Prevent SARS-COV-2 Infections in International Travelers and their Contacts.
    Cañete R; León LM; Rodríguez L
    MEDICC Rev; 2021 Apr; 23(2):10. PubMed ID: 33974608
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon-α2b induced anemia in severe coronavirus disease 2019 patients: a single centered, retrospective study.
    Li X; Liu T; Hai X; Li L
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):644-650. PubMed ID: 34698601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.
    Pandit A; Bhalani N; Bhushan BLS; Koradia P; Gargiya S; Bhomia V; Kansagra K
    Int J Infect Dis; 2021 Apr; 105():516-521. PubMed ID: 33713817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [
    Loginova SY; Shсhukina VN; Savenko SV; Borisevich SV
    Vopr Virusol; 2021 May; 66(2):123-128. PubMed ID: 33993682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study.
    Hao SR; Yan R; Zhang SY; Lian JS; Cai H; Zhang XL; Zheng L; Jia HY; Hu JH; Yu GD; Gu JQ; Ye CY; Jin CL; Lu YF; Xin JJ; Sheng JF; Yang YD
    J Zhejiang Univ Sci B; 2020 Aug.; 21(8):628-636. PubMed ID: 32748578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
    Pereda R; González D; Rivero HB; Rivero JC; Pérez A; López LDR; Mezquia N; Venegas R; Betancourt JR; Domínguez RE
    J Interferon Cytokine Res; 2020 Sep; 40(9):438-442. PubMed ID: 32960147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
    Wang N; Zhan Y; Zhu L; Hou Z; Liu F; Song P; Qiu F; Wang X; Zou X; Wan D; Qian X; Wang S; Guo Y; Yu H; Cui M; Tong G; Xu Y; Zheng Z; Lu Y; Hong P
    Cell Host Microbe; 2020 Sep; 28(3):455-464.e2. PubMed ID: 32707096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery.
    Pereda R; González D; Rivero HB; Rivero JC; Pérez A; Lopez LDR; Mezquia N; Venegas R; Betancourt JR; Domínguez RE; Nodarse H
    J Interferon Cytokine Res; 2020 Dec; 40(12):578-588. PubMed ID: 33337933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection.
    Sohn SY; Hearing J; Mugavero J; Kirillov V; Gorbunova E; Helminiak L; Mishra S; Mackow E; Hearing P; Reich NC; Kim HK
    mBio; 2021 Dec; 12(6):e0275621. PubMed ID: 34724828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.
    Schuhenn J; Meister TL; Todt D; Bracht T; Schork K; Billaud JN; Elsner C; Heinen N; Karakoese Z; Haid S; Kumar S; Brunotte L; Eisenacher M; Di Y; Lew J; Falzarano D; Chen J; Yuan Z; Pietschmann T; Wiegmann B; Uebner H; Taube C; Le-Trilling VTK; Trilling M; Krawczyk A; Ludwig S; Sitek B; Steinmann E; Dittmer U; Lavender KJ; Sutter K; Pfaender S
    Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35131898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area.
    Meng Z; Wang T; Chen L; Chen X; Li L; Qin X; Li H; Luo J
    Curr Top Med Chem; 2021; 21(10):920-927. PubMed ID: 33970846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
    Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G
    Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study.
    Bhushan B L S; Wanve S; Koradia P; Bhomia V; Soni P; Chakraborty S; Khobragade A; Joshi S; Mendiratta SK; Kansagra KK; Parihar A; Sharma S; Patel J;
    Int J Infect Dis; 2021 Oct; 111():281-287. PubMed ID: 34428542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.
    Barnabas RV; Brown ER; Bershteyn A; Stankiewicz Karita HC; Johnston C; Thorpe LE; Kottkamp A; Neuzil KM; Laufer MK; Deming M; Paasche-Orlow MK; Kissinger PJ; Luk A; Paolino K; Landovitz RJ; Hoffman R; Schaafsma TT; Krows ML; Thomas KK; Morrison S; Haugen HS; Kidoguchi L; Wener M; Greninger AL; Huang ML; Jerome KR; Wald A; Celum C; Chu HY; Baeten JM;
    Ann Intern Med; 2021 Mar; 174(3):344-352. PubMed ID: 33284679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon α-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: An open prospective cohort study.
    Xu N; Pan J; Sun L; Zhou C; Huang S; Chen M; Zhang J; Zhu T; Li J; Zhang H; Gao Y
    Front Immunol; 2022; 13():967716. PubMed ID: 35990674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
    Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
    García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
    Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.